[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Antelope Surgical Solutions, Inc\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":48},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100585753",false,"NCT06906471","A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS","Inclusion Criteria:\n\n* suspected prostate cancer warranting standard of care multi-core prostate biopsy\n\nExclusion Criteria:\n\n* Patients receiving same-day therapeutic Lutetium-177 or Actinium-225 PSMA receptor radiation isotope therapy treatment\n* Patients with pre-existing, impaired or abnormal hepatic function, renal function, cardiac function, and abnormal elevated temperature\n* Patients with a creatinine clearance cutoff (CrCl) of \\\u003C 60 mL\u002Fmin","MALE","18 Years","90 Years",{"count":18,"type":19},10,"ESTIMATED","INTERVENTIONAL",[22,23],"PHASE1","PHASE2","A Single-Arm, blinded, fluorescent PSMA histopathology trial of AS1986NS",[26,27,28],"Prostate Cancer","Prostate Cancer (Adenocarcinoma)","Fluorescence Imaging",[30,31,32,33,34],"fluorescent agent","PSMA","prostate surface membrane antigen","histopathology","fluorescence-guided surgery","NOT_YET_RECRUITING","2026-06-02",{"date":38,"type":39},"2026-06-04","ACTUAL",{"date":41,"type":19},"2026-06-05",{"date":43,"type":19},"2026-11-30",{"name":45,"class":46},"Antelope Surgical Solutions, Inc","INDUSTRY",3,""]